Arctigenin suppresses fibroblast activity and extracellular matrix deposition in hypertrophic scarring by reducing inflammation and oxidative stress

Jiang,Ling; Deng,Ying; Li,Wei; Lu,Yang

doi:10.3892/mmr.2020.11539

Arctigenin suppresses fibroblast activity and extracellular matrix deposition in hypertrophic scarring by reducing inflammation and oxidative stress

Authors:
- Ling Jiang
- Ying Deng
- Wei Li
- Yang Lu
View Affiliations

Affiliations: Department of Plastic Surgery, Chongqing University Central Hospital, Chongqing 400000, P.R. China
Published online on: September 25, 2020 https://doi.org/10.3892/mmr.2020.11539
Pages: 4783-4791
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypertrophic scars (HSs) are a progressive fibroproliferation disorder caused by abnormal tissue repair after deep skin injury, and are characterized by continuous activation of fibroblasts and excessive deposition of extracellular matrix. Arctigenin (ATG), a phytomedicine derived from certain plants, displays antifibrotic effects in certain diseases, such as oral submucous fibrosis and peritoneal fibrosis. In the present study, to determine the antifibrotic potential of ATG in HS, a bleomycin (BLM)‑induced skin fibrosis murine model was established. C57BL/6 mice were randomly divided into Control group, BLM group and BLM+ATG group. At 1 day post‑bleomycin induction, the BLM+ATG group was intraperitoneally injected with 3 mg/kg/day ATG for 28 consecutive days. Pathological changes in the skin tissues were observed by hematoxylin and eosin staining. Collagen content was determined using a Sircol Collagen assay kit. Immunofluorescence staining was performed to detect the expression of TGF‑β1 and α‑SMA. The expression changes of various factors were detected by reverse transcription‑quantitative PCR, western blotting and ELISA. Compared with the BLM group, ATG treatment significantly alleviated skin fibrosis by reducing dermal thickness, collagen content and expression levels of extracellular matrix‑related genes (collagen type I α1 chain, collagen type I α2 chain, connective tissue growth factor and plasminogen activator inhibitor‑1) in BLM‑induced fibrotic skin. ATG also inhibited the transformation of fibroblasts into myofibroblasts in vivo and decreased the expression of TGF‑β1 in BLM‑induced fibrotic skin. Furthermore, the contents of proinflammatory cytokines, including IL‑1β, IL‑4, IL‑6, TNF‑α and monocyte chemoattractant protein‑1, were significantly decreased in the BLM+ATG group compared with the BLM group. Redox imbalance and oxidative stress were also reversed by ATG in BLM‑induced fibrotic skin, as demonstrated by the upregulation of antioxidants (glutathione and superoxide dismutase) and downregulation of oxidants (malondialdehyde) in the BLM+ATG group compared with the BLM group. Moreover, the results indicated that the antioxidant effect of ATG may occur via activation of the nuclear factor erythroid‑2‑related factor 2/heme oxygenase‑1 signaling pathway. Collectively, the present study indicated that ATG could ameliorate skin fibrosis in a murine model of HS, which was partly mediated by reducing inflammation and oxidative stress. Therefore, ATG may serve as a therapeutic agent for HSs.

View Figures

View References

1	Zhang J, Li Y, Bai X, Li Y, Shi J and Hu D: Recent advances in hypertrophic scar. Histol Histopathol. 33:27–39. 2018.PubMed/NCBI
2	Niessen FB, Spauwen PH, Schalkwijk J and Kon M: On the nature of hypertrophic scars and keloids: A review. Plast Reconstr Surg. 104:1435–1458. 1999. View Article : Google Scholar : PubMed/NCBI
3	Tyack Z, Simons M, Spinks A and Wasiak J: A systematic review of the quality of burn scar rating scales for clinical and research use. Burns. 38:6–18. 2012. View Article : Google Scholar : PubMed/NCBI
4	Brown BC, McKenna SP, Siddhi K, McGrouther DA and Bayat A: The hidden cost of skin scars: Quality of life after skin scarring. J Plast Reconstr Aesthet Surg. 61:1049–1058. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bloemen MC, van der Veer WM, Ulrich MM, van Zuijlen PP, Niessen FB and Middelkoop E: Prevention and curative management of hypertrophic scar formation. Burns. 35:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
6	Jinnin M: Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol. 37:11–25. 2010. View Article : Google Scholar : PubMed/NCBI
7	Cho MK, Jang YP, Kim YC and Kim SG: Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: The role in TNF-alpha inhibition. Int Immunopharmacol. 4:1419–1429. 2004. View Article : Google Scholar : PubMed/NCBI
8	Gao Q, Yang M and Zuo Z: Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L. Acta Pharmacol Sin. 39:787–801. 2018. View Article : Google Scholar : PubMed/NCBI
9	Zhong Y, Lee K, Deng Y, Ma Y, Chen Y, Li X, Wei C, Yang S, Wang T, Wong NJ, et al: Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. Nat Commun. 10:45232019. View Article : Google Scholar : PubMed/NCBI
10	Zhu Z, Yan J, Jiang W, Yao XG, Chen J, Chen L, Li C, Hu L, Jiang H and Shen X: Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both β-amyloid production and clearance. J Neurosci. 33:13138–13149. 2013. View Article : Google Scholar : PubMed/NCBI
11	Lee JY and Kim CJ: Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits type I–IV allergic inflammation and pro-inflammatory enzymes. Arch Pharm Res. 33:947–957. 2010. View Article : Google Scholar : PubMed/NCBI
12	Lee JY, Cho BJ, Park TW, Park BE, Kim SJ, Sim SS and Kim CJ: Dibenzylbutyrolactone lignans from Forsythia koreana fruits attenuate lipopolysaccharide-induced inducible nitric oxide synthetase and cyclooxygenase-2 expressions through activation of nuclear factor-κb and mitogen-activated protein kinase in RAW264.7 cells. Biol Pharm Bull. 33:1847–1853. 2010. View Article : Google Scholar : PubMed/NCBI
13	Lin CY, Hsieh PL, Liao YW, Peng CY, Yu CC and Lu MY: Arctigenin reduces myofibroblast activities in oral submucous fibrosis by LINC00974 inhibition. Int J Mol Sci. 20:13282019. View Article : Google Scholar
14	Jin G, Su Y, Dong Q, Zhao X, Zhang L and Yan X: Arctigenin alleviates TGF-β1-induced epithelial-mesenchymal transition and PAI-1 expression via AMPK/NF-κB pathway in peritoneal mesothelial cells. Biochem Biophys Res Commun. 520:413–419. 2019. View Article : Google Scholar : PubMed/NCBI
15	Li A, Zhang X, Shu M, Wu M, Wang J, Zhang J, Wang R, Li P and Wang Y: Arctigenin suppresses renal interstitial fibrosis in a rat model of obstructive nephropathy. Phytomedicine. 30:28–41. 2017. View Article : Google Scholar : PubMed/NCBI
16	Li A, Wang J, Zhu D, Zhang X, Pan R and Wang R: Arctigenin suppresses transforming growth factor-β1-induced expression of monocyte chemoattractant protein-1 and the subsequent epithelial-mesenchymal transition through reactive oxygen species-dependent ERK/NF-κB signaling pathway in renal tubular epithelial cells. Free Radic Res. 49:1095–1113. 2015. View Article : Google Scholar : PubMed/NCBI
17	Li A, Wang J, Wu M, Zhang X and Zhang H: The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: Persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway. Eur J Pharmacol. 747:71–87. 2015. View Article : Google Scholar : PubMed/NCBI
18	Dudgeon C, Shreeram S, Tanoue K, Mazur SJ, Sayadi A, Robinson RC, Appella E and Bulavin DV: Genetic variants and mutations of PPM1D control the response to DNA damage. Cell Cycle. 12:2656–2664. 2013. View Article : Google Scholar : PubMed/NCBI
19	Sekiguchi A, Motegi SI, Fujiwara C, Yamazaki S, Inoue Y, Uchiyama A, Akai R, Iwawaki T and Ishikawa O: Inhibitory effect of kaempferol on skin fibrosis in systemic sclerosis by the suppression of oxidative stress. J Dermatol Sci. 96:8–17. 2019. View Article : Google Scholar : PubMed/NCBI
20	Fujiwara C, Uehara A, Sekiguchi A, Uchiyama A, Yamazaki S, Ogino S, Yokoyama Y, Torii R, Hosoi M, Suto C, et al: Suppressive regulation by MFG-E8 of latent transforming growth factor β-induced fibrosis via binding to αv integrin: Significance in the pathogenesis of fibrosis in systemic sclerosis. Arthritis Rheumatol. 71:302–314. 2019. View Article : Google Scholar : PubMed/NCBI
21	Thoua NM, Derrett-Smith EC, Khan K, Dooley A, Shi-Wen X and Denton CP: Gut fibrosis with altered colonic contractility in a mouse model of scleroderma. Rheumatology (Oxford). 51:1989–1998. 2012. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zhou CF, Yu JF, Zhang JX, Jiang T, Xu SH, Yu QY and Zhu QX: N-acetylcysteine attenuates subcutaneous administration of bleomycin-induced skin fibrosis and oxidative stress in a mouse model of scleroderma. Clin Exp Dermatol. 38:403–409. 2013. View Article : Google Scholar : PubMed/NCBI
24	Umasuthan N, Bathige SD, Revathy KS, Lee Y, Whang I, Choi CY, Park HC and Lee J: A manganese superoxide dismutase (MnSOD) from Ruditapes philippinarum: Comparative structural- and expressional-analysis with copper/zinc superoxide dismutase (Cu/ZnSOD) and biochemical analysis of its antioxidant activities. Fish Shellfish Immunol. 33:753–765. 2012. View Article : Google Scholar : PubMed/NCBI
25	Liu Q, Lu J, Lin J, Tang Y, Pu W, Shi X, Jiang S, Liu J, Ma Y, Li Y, et al: Salvianolic acid B attenuates experimental skin fibrosis of systemic sclerosis. Biomed Pharmacother. 110:546–553. 2019. View Article : Google Scholar : PubMed/NCBI
26	Ju W, Zhihong Y, Zhiyou Z, Qin H, Dingding W, Li S, Baowei Z, Xing W, Ying H and An H: Inhibition of alpha-SMA by the ectodomain of FGFR2c attenuates lung fibrosis. Mol Med. 18:992–1002. 2012. View Article : Google Scholar : PubMed/NCBI
27	Verrecchia F, Mauviel A and Farge D: Transforming growth factor-beta signaling through the Smad proteins: Role in systemic sclerosis. Autoimmun Rev. 5:563–569. 2006. View Article : Google Scholar : PubMed/NCBI
28	Zhang J, Qiao Q, Liu M, He T, Shi J, Bai X, Zhang Y, Li Y, Cai W, Han S, et al: IL-17 promotes scar formation by inducing macrophage infiltration. Am J Pathol. 188:1693–1702. 2018. View Article : Google Scholar : PubMed/NCBI
29	Shan S, Zhang Y, Wu M, Yi B, Wang J and Li Q: Naringenin attenuates fibroblast activation and inflammatory response in a mechanical stretch-induced hypertrophic scar mouse model. Mol Med Rep. 16:4643–4649. 2017. View Article : Google Scholar : PubMed/NCBI
30	Christmann RB and Lafyatis R: The cytokine language of monocytes and macrophages in systemic sclerosis. Arthritis Res Ther. 12:1462010. View Article : Google Scholar : PubMed/NCBI
31	Vona R, Giovannetti A, Gambardella L, Malorni W, Pietraforte D and Straface E: Oxidative stress in the pathogenesis of systemic scleroderma: An overview. J Cell Mol Med. 22:3308–3314. 2018. View Article : Google Scholar : PubMed/NCBI
32	Shroff A, Mamalis A and Jagdeo J: Oxidative stress and skin fibrosis. Curr Pathobiol Rep. 2:257–267. 2014. View Article : Google Scholar : PubMed/NCBI
33	Wu W, Peng G, Yang F, Zhang Y, Mu Z and Han X: Sulforaphane has a therapeutic effect in an atopic dermatitis murine model and activates the Nrf2/HO1 axis. Mol Med Rep. 20:1761–1771. 2019.PubMed/NCBI
34	Kavian N, Mehlal S, Jeljeli M, Saidu NEB, Nicco C, Cerles O, Chouzenoux S, Cauvet A, Camus C, Ait-Djoudi M, et al: The Nrf2-antioxidant response element signaling pathway controls fibrosis and autoimmunity in scleroderma. Front Immunol. 9:18962018. View Article : Google Scholar : PubMed/NCBI
35	Katz L and Baltz RH: Natural product discovery: Past, present, and future. J Ind Microbiol Biotechnol. 43:155–176. 2016. View Article : Google Scholar : PubMed/NCBI
36	Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, et al: Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv. 33:1582–1614. 2015. View Article : Google Scholar : PubMed/NCBI
37	Won YD, Na MK, Kim CH, Kim JM, Cheong JH, Ryu JI and Han MH: The frontal skull Hounsfield unit value can predict ventricular enlargement in patients with subarachnoid haemorrhage. Sci Rep. 8:101782018. View Article : Google Scholar : PubMed/NCBI
38	Liu S, Taghavi R and Leask A: Connective tissue growth factor is induced in bleomycin-induced skin scleroderma. J Cell Commun Signal. 4:25–30. 2010. View Article : Google Scholar : PubMed/NCBI
39	Chung EJ, McKay-Corkum G, Chung S, White A, Scroggins BT, Mitchell JB, Mulligan-Kehoe MJ and Citrin D: Truncated plasminogen activator inhibitor-1 protein protects from pulmonary fibrosis mediated by irradiation in a murine model. Int J Radiat Oncol Biol Phys. 94:1163–1172. 2016. View Article : Google Scholar : PubMed/NCBI
40	Lichtman MK, Otero-Vinas M and Falanga V: Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis. Wound Repair Regen. 24:215–222. 2016. View Article : Google Scholar : PubMed/NCBI
41	Selvarajah B, Azuelos I, Platé M, Guillotin D, Forty EJ, Contento G, Woodcock HV, Redding M, Taylor A, Brunori G, et al: mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-β₁-induced collagen biosynthesis. Sci Signal. 12:eaav30482019. View Article : Google Scholar : PubMed/NCBI
42	Lima JDCC, Simoes E, de Castro G, Morais MRPT, de Matos-Neto EM, Alves MJ, Pinto NI, Figueredo RG, Zorn TMT, Felipe-Silva AS, et al: Tumour-derived transforming growth factor-β signalling contributes to fibrosis in patients with cancer cachexia. J Cachexia Sarcopenia Muscle. 10:1045–1059. 2019. View Article : Google Scholar : PubMed/NCBI
43	Zhong L, Simard MJ and Huot J: Endothelial microRNAs regulating the NF-κB pathway and cell adhesion molecules during inflammation. FASEB J. 32:4070–4084. 2018. View Article : Google Scholar : PubMed/NCBI
44	Doridot L, Jeljeli M, Chêne C and Batteux F: Implication of oxidative stress in the pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis. Redox Biol. 25:1011222019. View Article : Google Scholar : PubMed/NCBI
45	Zhou CF, Zhou DC, Zhang JX, Wang F, Cha WS, Wu CH and Zhu QX: Bleomycin-induced epithelial-mesenchymal transition in sclerotic skin of mice: Possible role of oxidative stress in the pathogenesis. Toxicol Appl Pharmacol. 277:250–258. 2014. View Article : Google Scholar : PubMed/NCBI
46	Czerska M, Mikolajewska K, Zieliński M, Gromadzińska J and Wąsowicz W: Today's oxidative stress markers. Med Pr. 66:393–405. 2015. View Article : Google Scholar : PubMed/NCBI
47	Yang HY and Lee TH: Antioxidant enzymes as redox-based biomarkers: A brief review. BMB Rep. 48:200–208. 2015. View Article : Google Scholar : PubMed/NCBI
48	Liu Z, Wang J, Huang E, Gao S, Li H, Lu J, Tian K, Little PJ, Shen X, Xu S and Liu P: Tanshinone IIA suppresses cholesterol accumulation in human macrophages: Role of heme oxygenase-1. J Lipid Res. 55:201–213. 2014. View Article : Google Scholar : PubMed/NCBI